Connect your AI

Acadia Pharmaceuticals ACAD Price / book

Price / book at other companies

BiogenBIIB

1.4×+0.3×

Neurocrine BiosciencesNBIX

3.9×-0.5×

Catalyst PharmaceuticalCPRX

3×-0.7×

TG TherapeuticsTGTX

9.1×-17.0×

Arrowhead ResearchARWR

14.3×+11.7×

Amneal Pharmaceuticals, Inc.AMRX

94.1×+93.1×

Other financials

Income statement

Revenue$268.1M+9.7%

Gross profit$243.3M+8.6%

Operating income-$4.6M-124%

Net income$3.6M-80.8%

EPS (diluted)$0.02-81.8%

Balance sheet

Cash & equivalents$282.2M+29.6%

Total debt$50.8M-9.3%

Total equity$1.2B+63.1%

Total assets$1.6B+41.8%

Cash flow

Operating cash flow$34.0M+67.2%

CapEx$5.2M—

Free cash flow$28.8M+41.6%

Valuation

Market cap$3.87B+37.0%

Profitability

Gross margin91.5%-0.6pp

Operating margin7.4%-16.2pp

Net margin34.3%+11.3pp

FCF margin18.9%—

Returns & leverage

Return on equity37.3%+0.1pp

Debt / equity0×0.0×

Current ratio3.6×+0.7×

Where this comes from

Calculated from Acadia Pharmaceuticals’s reported figures.

market cap/total stockholders equity=3×

Based on the most recent quarter.

The official record: Acadia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Acadia Pharmaceuticals's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Acadia Pharmaceuticals's price / book?: Acadia Pharmaceuticals (ACAD) reported price / book of 3× in Q1 2026.
How has Acadia Pharmaceuticals's price / book changed year-over-year?: Acadia Pharmaceuticals's price / book decreased by 16.0% year-over-year, from 3.6× to 3×.
What is the long-term trend for Acadia Pharmaceuticals's price / book?: Over 5 years (2020 to 2025), Acadia Pharmaceuticals's price / book has grown at a -23.1% compound annual growth rate (CAGR), from 13.7× to 3.7×.
What does price / book mean?: Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.